Buprenorphine

Buprenorphine is a morphinane alkaloid that is 7,8-dihydromorphine 6-O-methyl ether in which positions 6 and 14 are joined by a -CH2CH2- bridge, one of the hydrogens of the N-methyl group is substituted by cyclopropyl, and a hydrogen at position 7 is substituted by a 2-hydroxy-3,3-dimethylbutan-2-yl group. Buprenorphine is a synthetic opioid medication mainly used to treat opioid use disorder (OUD) and manage acute or chronic pain. Developed in the late 1960s, it was approved by the FDA in 2002 for opioid addiction treatment, representing a significant advance in medication-assisted treatment (MAT). It is grouped under the following drug class(es): Controlled drug substances, Opioid dependence agents, QTc-prolonging agents and Schedule III controlled substances. Its therapeutic use is listed as analgesics. The directory classifies it as a commercial API with a semi-synthetic source/manufacturing origin. Other names for this substance include Subutex, Temgesic and Brixadi. It is listed as a controlled drug substance (Schedule III). Its PubChem CID is 644073.